Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Transfer of LLPs from Chugai “Our Ticket to Admission” into Pharma Business: Taiyo Pharma COO
The transfer of marketing authorizations for 13 long-listed products (LLPs) from Chugai Pharmaceutical will be “Taiyo Pharma’s ticket to admission” into the pharmaceutical business, said Taiyo Pharma COO Masao Arima on November 15. He also expressed his determination to expand…
To read the full story
Related Article
- Chugai Completes Transfer of 13 Off-Patent Brands to Taiyo
January 10, 2019
- Taiyo Pharma Eyeing 10 Trillion Yen Japanese Market, Looking to Use In-House Technologies to Develop New Products: COO
January 10, 2018
- Chugai Executes Asset Transfer for 13 Off-Patent Brands
January 9, 2018
- Chugai to Offload 13 Off-Patent Brands to Taiyo Holdings
November 15, 2017
BUSINESS
- Astellas Expands AI Drug Discovery to TPDs, Engineered Proteins
July 30, 2026
- Regeneron Japan Files First Dual-AAV Therapy for Genetic Hearing Loss
July 30, 2026
- Shionogi’s Xocova Debuts in US for COVID-19 PEP
July 30, 2026
- Some Drug Plants Halt Operations after Kumamoto Temblor, Supplies Unaffected
July 30, 2026
- Leqembi Global Sales Rise to 29.3 Billion Yen in April-June: Eisai
July 30, 2026
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…